Trials / Unknown

UnknownNCT05930912

Psychiatric Orders in Psychoanalytic Treatment of ASD

Status: Unknown
Phase: —
Study type: Observational
Enrollment: 1 (actual)

Sponsor: Yang I. Pachankis, PhD · Individual
Sex: All
Age: 18 Years – 70 Years
Healthy volunteers: —

Summary

Autism Spectrum Disorder (ASD) is often accompanied by a variety of other symptoms, such as bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), Social Anxiety Disorder (SAD), Avoidant Personality Disorder (AvPD), Obsessive Compulsive Disorder (OCD), etc. The behavioral and social complications often marginalize the population, impact on life satisfaction, undermined societal values that impact on economic and financial fairness, and so forth. Furthermore, persons with ASD are neurodiverse from standardized pharmacological and clinical cares, and are interpreted disadvantaged in the context of neurotypical treatments. The research protocol aims to differentiate the neuropharmacological implications of ASD from its behavioral and social implications. Such a differentiation is beneficial to the quality of care for neurodiverse population, both in terms of precision treatment in medical settings, and in terms of psychotherapeutic treatment efficacy in the interpretation of behavioral and social traits. The study protocol continues from the adverse event of the participant in NCT05711810 trial, after the positive immunological results in the NCT05839236 trial. The intervention medicine continues from Sertraline adjusted on the choice of Selective Serotonin Reuptake Inhibitor (SSRI) in the previous two trials for complex post-traumatic stress disorder (CPTSD) of the participant, and its combined used with Duloxetine in the choice of Selective Norephedrine Reuptake Inhibitor (SNRI) for norephedrine regulations. The hypothesized target is on the discrete psychiatric intervention centered approach to ASD treatment care. In the PRC where the study is being carried out, amphetamine class medicines are strictly prohibited and defined as illegal substances, regardless of their only proven effect for ASD patient care. Contributed by the sociostructural elements and necessities, black market amphetamine and ketamine have not only emerged in the regime for decades, but also have become a lucrative business. Their recreational uses are also sometimes accompanied by real necessities and needs; black markets cater to the needs but guidance on the usages is based on word-of-mouth stories without professional medical assistances. There is one case the Principal Investigator (PI) collected, that one person, possibly under depression contributed by PTSD, took relatively high dosage of amphetamine and went into a state of psychosis with overwhelming persecution mania. The study protocol, Psychiatric Orders in Psychoanalytic Treatment of ASD, is therefore designed for an evidence-based approach in treating complex psychiatric disorders with psychoanalytic guidance.

Conditions

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Psychoanalysis	Case-specific psychoanalysis is performed, including the participant's background during birth.
DRUG	sertraline 50mg	After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.
DRUG	Duloxetine 20 MG	Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.
BEHAVIORAL	Cognitive Behavioral Therapy	CBT is tailored to the participant's current activities and life decisions.

Timeline

Start date: 2023-06-01
Primary completion: 2023-09-01
Completion: 2023-12-01
First posted: 2023-07-05
Last updated: 2023-07-05

Locations

1 site across 1 country: China

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT05930912. Inclusion in this directory is not an endorsement.